Literature DB >> 16766651

Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3.

Monika Kasprzycka1, Michal Marzec, Xiaobin Liu, Qian Zhang, Mariusz A Wasik.   

Abstract

The mechanisms of malignant cell transformation mediated by the oncogenic, chimeric nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) tyrosine kinase remain only partially understood. Here we report that the NPM/ALK-carrying T cell lymphoma (ALK+TCL) cells secrete IL-10 and TGF-beta and express FoxP3, indicating their T regulatory (Treg) cell phenotype. The secreted IL-10 suppresses proliferation of normal immune, CD3/CD28-stimulated peripheral blood mononuclear cells and enhances viability of the ALK+TCL cells. The Treg phenotype of the affected cells is strictly dependent on NPM/ALK expression and function as demonstrated by transfection of the kinase into BaF3 cells and inhibition of its enzymatic activity and expression in ALK+TCL cells. NPM/ALK, in turn, induces the phenotype through activation of its key signal transmitter, signal transducer and activator of transcription 3 (STAT3). These findings identify a mechanism of NPM/ALK-mediated oncogenesis based on induction of the Treg phenotype of the transformed CD4(+) T cells. These results also provide an additional rationale to therapeutically target the chimeric kinase and/or STAT3 in ALK+TCL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16766651      PMCID: PMC1502562          DOI: 10.1073/pnas.0603507103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells.

Authors:  Pedro L Vieira; Jillian R Christensen; Sophie Minaee; Emma J O'Neill; Franck J Barrat; André Boonstra; Thomas Barthlott; Brigitta Stockinger; David C Wraith; Anne O'Garra
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

2.  Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells.

Authors:  Kennosuke Karube; Koichi Ohshima; Takeshi Tsuchiya; Takahiro Yamaguchi; Riko Kawano; Junji Suzumiya; Atae Utsunomiya; Mine Harada; Masahiro Kikuchi
Journal:  Br J Haematol       Date:  2004-07       Impact factor: 6.998

Review 3.  The STATs of cancer--new molecular targets come of age.

Authors:  Hua Yu; Richard Jove
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

Review 4.  Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer?

Authors:  Ana M Gamero; Howard A Young; Robert H Wiltrout
Journal:  Cancer Cell       Date:  2004-02       Impact factor: 31.743

5.  Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma.

Authors:  Neil A Marshall; Linsey E Christie; Laura R Munro; Dominic J Culligan; Peter W Johnston; Robert N Barker; Mark A Vickers
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

6.  Identification of NPM-ALK interacting proteins by tandem mass spectrometry.

Authors:  David K Crockett; Zhaosheng Lin; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Oncogene       Date:  2004-04-08       Impact factor: 9.867

7.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells.

Authors:  Tianhong Wang; Guilian Niu; Marcin Kortylewski; Lyudmila Burdelya; Kenneth Shain; Shumin Zhang; Raka Bhattacharya; Dmitry Gabrilovich; Richard Heller; Domenico Coppola; William Dalton; Richard Jove; Drew Pardoll; Hua Yu
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

8.  Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity.

Authors:  James Turkson; Joon S Kim; Shumin Zhang; Jing Yuan; Mei Huang; Matthew Glenn; Eric Haura; Said Sebti; Andrew D Hamilton; Richard Jove
Journal:  Mol Cancer Ther       Date:  2004-03       Impact factor: 6.261

Review 9.  Interleukin-10 and related cytokines and receptors.

Authors:  Sidney Pestka; Christopher D Krause; Devanand Sarkar; Mark R Walter; Yufang Shi; Paul B Fisher
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  56 in total

1.  STAT3: a multifaceted oncogene.

Authors:  David E Levy; Giorgio Inghirami
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-26       Impact factor: 11.205

2.  Nonredundant roles for Stat5a/b in directly regulating Foxp3.

Authors:  Zhengju Yao; Yuka Kanno; Marc Kerenyi; Geoffrey Stephens; Lydia Durant; Wendy T Watford; Arian Laurence; Gertraud W Robinson; Ethan M Shevach; Richard Moriggl; Lothar Hennighausen; Changyou Wu; John J O'Shea
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

Review 3.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

4.  Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP.

Authors:  Mamta Gupta; Matthew J Maurer; Linda E Wellik; Mark E Law; Jing Jing Han; Nazan Ozsan; Ivana N Micallef; Ahmet Dogan; Thomas E Witzig
Journal:  Blood       Date:  2012-09-27       Impact factor: 22.113

5.  The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes.

Authors:  Qian Zhang; Fang Wei; Hong Yi Wang; Xiaobin Liu; Darshan Roy; Qun-Bin Xiong; Shuguang Jiang; Andrew Medvec; Gwenn Danet-Desnoyers; Christopher Watt; Ewa Tomczak; Michael Kalos; James L Riley; Mariusz A Wasik
Journal:  Am J Pathol       Date:  2013-12       Impact factor: 4.307

6.  Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS.

Authors:  Qian Zhang; Hongyi Wang; Kanchan Kantekure; Jennifer C Paterson; Xiaobin Liu; Andras Schaffer; Chrystal Paulos; Michael C Milone; Niels Odum; Suzanne Turner; Teresa Marafioti; Mariusz A Wasik
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

7.  Impact of the N-Terminal Domain of STAT3 in STAT3-Dependent Transcriptional Activity.

Authors:  Tiancen Hu; Jennifer E Yeh; Luca Pinello; Jaison Jacob; Srinivas Chakravarthy; Guo-Cheng Yuan; Rajiv Chopra; David A Frank
Journal:  Mol Cell Biol       Date:  2015-07-13       Impact factor: 4.272

8.  Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.

Authors:  Michal Marzec; Krzysztof Halasa; Xiaobin Liu; Hong Y Wang; Mangeng Cheng; Donald Baldwin; John W Tobias; Stephen J Schuster; Anders Woetmann; Qian Zhang; Suzanne D Turner; Niels Ødum; Mariusz A Wasik
Journal:  J Immunol       Date:  2013-11-11       Impact factor: 5.422

9.  Staphylococcal enterotoxin B in vivo modulates both gamma interferon receptor expression and ligand-induced activation of signal transducer and activator of transcription 1 in T cells.

Authors:  R Plaza; J L Rodriguez-Sanchez; C Juarez
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

Review 10.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.